News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,127 Results
Type
Article (14741)
Company Profile (281)
Press Release (256105)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79965)
Career Advice (175)
Deals (13320)
Drug Delivery (35)
Drug Development (50597)
Employer Resources (31)
FDA (5748)
Job Trends (5214)
News (145223)
Policy (10202)
Tag
Academia (927)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21801)
ALS (68)
Alzheimer's disease (853)
Antibody-drug conjugate (ADC) (108)
Approvals (5774)
Artificial intelligence (133)
Autoimmune disease (19)
Automation (5)
Bankruptcy (109)
Best Places to Work (4588)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (164)
Cancer (1521)
Cardiovascular disease (121)
Career advice (155)
Career pathing (3)
CAR-T (122)
Cell therapy (338)
Cervical cancer (9)
Clinical research (41245)
Collaboration (557)
Compensation (275)
Complete response letters (13)
COVID-19 (1047)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1595)
Denatured (11)
Depression (32)
Diabetes (143)
Diagnostics (1316)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (87)
Drug pricing (30)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30125)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (48955)
Executive appointments (472)
FDA (6515)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (513)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (375)
Government (1132)
Grass and pollen (2)
Guidances (66)
Healthcare (6668)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1113)
Inflammatory bowel disease (119)
Inflation Reduction Act (9)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7304)
IRA (11)
Job creations (910)
Job search strategy (144)
Kidney cancer (7)
Labor market (9)
Layoffs (220)
Leadership (3)
Legal (1438)
Liver cancer (34)
Lung cancer (208)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (59)
Medical device (2651)
Medtech (2652)
Mergers & acquisitions (6353)
Metabolic disorders (407)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1272)
NextGen: Class of 2025 (2051)
Non-profit (899)
Now hiring (22)
Obesity (200)
Opinion (105)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (61)
Parkinson's disease (121)
Partnered (8)
Patents (136)
Patient recruitment (82)
Peanut (35)
People (25796)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14563)
Phase II (19195)
Phase III (12121)
Pipeline (915)
Policy (50)
Postmarket research (856)
Preclinical (6174)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (297)
Real estate (1484)
Recruiting (12)
Regulatory (8763)
Reports (17)
Research institute (966)
Resumes & cover letters (21)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (67)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (118)
Sponsored (12)
Startups (1997)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (13)
The Weekly (37)
Vaccines (219)
Venture capitalists (32)
Weight loss (114)
Women's health (15)
Worklife (2)
Date
Today (17)
Last 7 days (556)
Last 30 days (1730)
Last 365 days (19314)
2025 (6931)
2024 (20609)
2023 (22485)
2022 (27061)
2021 (28166)
2020 (23572)
2019 (16402)
2018 (11902)
2017 (13883)
2016 (11970)
2015 (14472)
2014 (10485)
2013 (7563)
2012 (7632)
2011 (7721)
2010 (7504)
Location
Africa (160)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17592)
Australia (2962)
California (4046)
Canada (1172)
China (372)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37549)
Florida (493)
Georgia (121)
Idaho (16)
Illinois (239)
India (10)
Indiana (95)
Iowa (2)
Japan (78)
Kansas (66)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (496)
Massachusetts (3211)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1003)
New Mexico (12)
New York (1083)
North Carolina (567)
North Dakota (5)
Northern California (1799)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (762)
Puerto Rico (6)
Rhode Island (19)
South America (219)
South Carolina (5)
Southern California (1559)
Tennessee (25)
Texas (469)
United States (13813)
Utah (56)
Virginia (84)
Washington D.C. (31)
Washington State (361)
Wisconsin (16)
271,127 Results for "spur therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
May 2, 2025
·
1 min read
Press Releases
Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
April 28, 2025
·
2 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Press Releases
Spur Therapeutics to Participate in Upcoming Investor Conferences
November 19, 2024
·
1 min read
Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Spur Therapeutics, formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference being held on June 27th, 2024.
June 20, 2024
·
1 min read
Press Releases
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
January 23, 2025
·
2 min read
Press Releases
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
February 3, 2025
·
5 min read
Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson’s Disease Research Program
Spur Therapeutics, formerly Freeline Therapeutics, today announced new data from its GBA1 Parkinson’s disease research program demonstrating that its rationally engineered GCase85 enzyme reduces the accumulation of α-Synuclein, a protein that plays a significant role in the development and progression of Parkinson’s disease, more effectively than wildtype glucocerebrosidase (GCase) in in vitro studies.
July 1, 2024
·
5 min read
Press Releases
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
December 4, 2024
·
5 min read
Press Releases
Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™
February 4, 2025
·
6 min read
1 of 27,113
Next
